PWM
SMMT icon

Parkworth Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Parkworth Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$85 Hold
4
– – ﹤0.01% 1177
2025
Q1 		$77 Buy
+4
New +$80 ﹤0.01% 1014

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Parkworth Wealth Management's SMMT Position: Q2 2025 in Review

Parkworth Wealth Management held its Summit Therapeutics (SMMT) position steady in Q2 2025 at 4 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #1177.

Parkworth Wealth Management first reported a position in SMMT in Q1 2025 and has held it in 2 quarters since. 238 funds tracked by Wall St. Rank hold SMMT as of Q2 2025.

  • Parkworth Wealth Management held 4 shares of Summit Therapeutics worth $85 as of Q2 2025.
  • Parkworth Wealth Management left its Summit Therapeutics share count unchanged in Q2 2025.
  • Summit Therapeutics made up ﹤0.01% of Parkworth Wealth Management's portfolio in Q2 2025, its #1177 holding.
  • Parkworth Wealth Management first reported a position in Summit Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 238 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2025.

Based on Parkworth Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.